The design of drugs that target different components of the Akt signaling pathway is of great value for the therapeutic treatment of cancer [13]–[17], [50], [73], [74], and Akt-IV has been shown to exhibit potent anticancer and antiviral activity [13]–[17], [50], [73], [74]. The gene discussed is AKT1; the disease is cancer.